CENTOGENE N.V. (CNTG): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNTG Stock Summary
- With a price/sales ratio of 0.21, CENTOGENE NV has a higher such ratio than just 6.7% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, CENTOGENE NV is reporting a growth rate of 197.28%; that's higher than 92.46% of US stocks.
- As for revenue growth, note that CNTG's revenue has grown -61.7% over the past 12 months; that beats the revenue growth of merely 3.26% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to CENTOGENE NV, a group of peers worth examining would be APPN, LVOX, NPCE, BASE, and SONM.
- CNTG's SEC filings can be seen here. And to visit CENTOGENE NV's official web site, go to www.centogene.com.
CNTG Price Target
For more insight on analysts targets of CNTG, see our CNTG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.32 | Average Broker Recommendation | 1 (Strong Buy) |
CNTG Stock Price Chart Interactive Chart >
CNTG Price/Volume Stats
| Current price | $0.73 | 52-week high | $4.30 |
| Prev. close | $0.73 | 52-week low | $0.61 |
| Day low | $0.63 | Volume | 14,800 |
| Day high | $0.75 | Avg. volume | 19,198 |
| 50-day MA | $1.06 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 19.71M |
CENTOGENE N.V. (CNTG) Company Bio
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Latest CNTG News From Around the Web
Below are the latest news stories about CENTOGENE NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - PharmaCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer and General Manager - Pharma, who will join the Company on March 15, 2023. Mr. Rentsch is a globally experienced industry leader with over 25 years of experience in the pharmaceutical and life sciences sector. |
CENTOGENE to Participate in Upcoming Conferences in MarchCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for March 2023. CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees |
Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year. |
In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) geneThe observational EFRONT study is increasing the number of sites to expand access to geographic specific clinicians actively engaged in FTD researchThe study aims to enroll and genetically test over 2,500 FTD patients across seven countriesThere are currently no FDA-approved treatments for FTD, one of the over 7,000 rare diseases affecting a tota |
CENTOGENE Regains Compliance With Nasdaq Listing RequirementsCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5 |
CNTG Price Returns
| 1-mo | -33.64% |
| 3-mo | -21.51% |
| 6-mo | -34.82% |
| 1-year | -82.66% |
| 3-year | -96.35% |
| 5-year | N/A |
| YTD | -21.51% |
| 2022 | -82.21% |
| 2021 | -51.50% |
| 2020 | 7.05% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...